Novartis AG (NVS)
After hours:
| Previous Close | 99.07 |
| Open | 99.65 |
| Bid | 98.00 x 900 |
| Ask | 100.70 x 800 |
| Day's Range | 99.26 - 99.78 |
| 52 Week Range | 92.19 - 108.78 |
| Volume | |
| Avg. Volume | 1,608,406 |
| Market Cap | 203.225B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 22.64 |
| EPS (TTM) | 4.40 |
| Earnings Date | Jul 18, 2024 |
| Forward Dividend & Yield | 3.78 (3.81%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | 114.51 |
GlobeNewswireArvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
The TelegraphQuestor: this medical stock is expensive – but worth paying for
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.
ZacksAlnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
